Wondering how Queenie invests in AI without picking individual stocks? Here’s how I get AI exposure through ETFs, manage risk, and build a balanced portfolio.

How to invest in AI and tech with ETFs

Wondering how much cash to hold alongside your ETFs? Learn what a cash buffer is, why it matters, the trade-offs, and how to find the right amount for your investing strategy — without guesswork.

How much of a cash buffer should I hold alongside ETFs?

What are the best tech stocks to invest now in the US market?

US stock

Hi, I’m fairly new to investing and this is a dumb question but what is the difference when investing in the AU shares vs US shares tab? 
Is it that the AU shares are funds held by brokers in Aus and the US one is US brokers? Is there a better option for an Aus investor? What are the tax implications of investing in US EFTs over Aus ones? 
Thanks, Molly

AU vs US shares

I currently hold shares in various Australian ETFs including VDHG, NDQ, ETHI, etc. My question is whether I should also be investing in US ETFs such as VOO. If these ETFs are made up of mostly the same/similar companies, are there any other benefits in choosing to go with US and AUS ETFs? Thanks!

Aus v US shares - smart to invest in both?

Guardant Health, Inc. (GH:US) Share Price | Pearler

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

The iShares S&P 500 ETF seeks to track the investment results of an index composed of large-capitalisation U.S. equities.

iShares S&P 500 Etf

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

Vanguard Australian Shares Index ETF (ASX: VAS) seeks to track the performance of the ASX 300 index before account fees, expenses, and taxes. The index tracks the top 300 companies on the Australian Securities Exchange (ASX). These are mostly large and established Australian companies. It is a popular choice among passive individual investors who don't have the time or the expertise to actively invest in stocks.

Vanguard Australian Shares Index Etf

Gaming & Hospitality Acquisition Corp. is a blank check company. The Company created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company focuses on the gaming and hospitality sectors. The Company has no operations and has not generated revenues.

GAMING & HOSPITALITY ACQUI-A

The Gabelli Multimedia Trust Inc. (the Fund) is a United States-based non-diversified closed-end management investment company. The Fund's investment objective is long term growth of capital. The Fund will invest at least 80% of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing and entertainment industries. The Fund also invests in various industries, including cable, the United States Government obligations, computer software and services, broadcasting, hotels and gaming, wireless communications, satellite, electronics, publishing, consumer services, financial services, computer hardware, equipment, business services, retail, diversified industrial, consumer products, food and beverage, real estate investment trusts and real estate. The Fund's investment advisor is Gabelli Funds, LLC.

GABELLI MULTIMEDIA TRUST INC

Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer globally through the use of its proprietary tests, vast data sets and advanced analytics. The Company has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. It also has developed Guardant360 TissueNext tissue test for advanced-stage cancer, Guardant Reveal blood test to detect residual and recurring disease in early-stage cancer patients, and Guardant360 Response blood test to predict patient response to immunotherapy or targeted therapy eight weeks earlier than current standard-of-care imaging. The Company’s GuardantINFORM platform is used to help biopharmaceutical companies accelerate precision oncology drug development through the use of this in-silico research platform to unlock further insights into tumor evolution and treatment resistance across various biomarker-driven cancers.

Guardant Health, Inc.

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company's other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.

Gilead Sciences Inc.

Global X Lithium ETF (the Fund) seeks to provide investment results that correspond generally to the price and yield performance of the Solactive Global Lithium Index (the Index). The Index is free float adjusted, liquidity tested and market capitalization-weighted index that is designed to measure broad based equity market performance of global companies involved in the lithium industry, as defined by Structured Solutions AG. The Fund will normally invest at least 80% of its total assets in the securities of the Index and in depositary receipts based on the securities in the Index. The Fund will concentrate its investments (will hold 25% or more of its total assets) in a particular industry or group of industries to approximately the same extent that the Index is concentrated. The Index is sponsored by Structured Solutions AG, the index provider. The Fund’s investment adviser is Global X Management Company LLC.

Global X Lithium & Battery Tech ETF

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. It develops T-cell therapies for solid tumors and has reported responses in multiple solid tumor indications. Its platform helps to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. Its cell therapy candidates include genetically engineered T-cell receptors (TCRs) and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Its MAGE-A4 cell therapy franchise includes T-cell therapy products targeting solid tumor indications in which the MAGE-A4 antigen is expressed, with responses seen in eight indications (head and neck, esophagogastric junction, non-small cell lung cancer-squamous, synovial sarcoma, melanoma, urothelial, ovarian and myxoid/round cell liposarcoma indications).

Adaptimmune Therapeutics plc

Axonics, Inc. is a medical technology company, which develops and commercializes products to treat bladder and bowel dysfunction. It has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10 cubic centimeters (cc) in volume, utilizes constant current stimulation, a recharge-free patient remote control and offers broad magnetic resonance imaging (MRI) access. Its SNM systems include an easy-to-use wireless patient remote control that does not require recharging or replacement batteries. It also offers a clinician programmer that guides the implanting physician through lead placement and stimulation programming.

Axonics Modulation Technologies Inc

Denali Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company’s clinical-stage programs include Antibody Transport Vehicle (ATV): triggering receptors expressed on myeloid cells 2 (TREM2), Protein Transport Vehicle (PTV): progranulin (PGRN), eukaryotic initiation factor 2 B (eIF2B), receptor-interacting serine/threonine protein kinase 1 (RIPK1), Enzyme Transport Vehicle (ETV): iduronate 2-sulfatase (IDS) and leucine-rich repeat kinase 2 (LRRK2), which are in various Phases ranging from Phase I through Phase III. The Company’s product candidates include DNL310, TAK-594/DNL593, TAK-920/DNL919, BIIB122/DNL151, DNL343, SAR443820/DNL788 and SAR443122/DNL758. The Company engineers its product candidates to cross the BBB, and act directly in the brain.

Back

GH

Description

Show more

Performance

$28.08

▼ -$3.46 (-10.97%)

1M

ALL TIME

GRAPH

TABLE

GRAPH

TABLE

Quick facts

N/A Growth

N/A

$15 AUD minimum investment

$0 USD median portfolio

Costs

N/A

Community insights

General statistics

.css-1ourppy{box-sizing:border-box;margin:0;min-width:0;font-size:14px;line-height:22px;font-weight:500;-webkit-transition:all 0.3s ease;transition:all 0.3s ease;display:inline;color:var(--primaryDark);}0 investors hold GH

N/A average time between investments

N/A average holding per investor

N/A since last community investment

Demographics

Income of investors

-

-

-

-

-

Age of investors

-

-

-

Legal gender of investors

0% male

0% female

Related items

GILD

LIT

ADAP

AXNX

DNLI

Learn more

How to invest in AI and tech with ETFs

How much of a cash buffer should I hold alongside ETFs?

US stock

K-Investor

•

July 27th, 2022

AU vs US shares

Molly Pearse

•

January 29th, 2023

Aus v US shares - smart to invest in both?

Stephanie Varga

•

May 16th, 2023

0 investors hold GH